Logo image of ICLR

ICON PLC (ICLR) Stock Fundamental Analysis

NASDAQ:ICLR - Nasdaq - IE0005711209 - Common Stock - Currency: USD

187.01  -8 (-4.1%)

After market: 187.01 0 (0%)

Fundamental Rating

5

Overall ICLR gets a fundamental rating of 5 out of 10. We evaluated ICLR against 54 industry peers in the Life Sciences Tools & Services industry. Both the profitability and the financial health of ICLR get a neutral evaluation. Nothing too spectacular is happening here. ICLR has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

In the past year ICLR was profitable.
In the past year ICLR had a positive cash flow from operations.
In the past 5 years ICLR has always been profitable.
ICLR had a positive operating cash flow in each of the past 5 years.
ICLR Yearly Net Income VS EBIT VS OCF VS FCFICLR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

1.2 Ratios

ICLR has a Return On Assets of 4.53%. This is in the better half of the industry: ICLR outperforms 77.78% of its industry peers.
Looking at the Return On Equity, with a value of 7.98%, ICLR belongs to the top of the industry, outperforming 81.48% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 6.71%, ICLR is in the better half of the industry, outperforming 74.07% of the companies in the same industry.
ICLR had an Average Return On Invested Capital over the past 3 years of 5.80%. This is significantly below the industry average of 16.41%.
The last Return On Invested Capital (6.71%) for ICLR is above the 3 year average (5.80%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 4.53%
ROE 7.98%
ROIC 6.71%
ROA(3y)3.74%
ROA(5y)4.36%
ROE(3y)6.96%
ROE(5y)8.15%
ROIC(3y)5.8%
ROIC(5y)6.92%
ICLR Yearly ROA, ROE, ROICICLR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30

1.3 Margins

Looking at the Profit Margin, with a value of 9.25%, ICLR is in the better half of the industry, outperforming 75.93% of the companies in the same industry.
ICLR's Profit Margin has declined in the last couple of years.
The Operating Margin of ICLR (14.54%) is better than 75.93% of its industry peers.
In the last couple of years the Operating Margin of ICLR has remained more or less at the same level.
ICLR's Gross Margin of 29.08% is on the low side compared to the rest of the industry. ICLR is outperformed by 74.07% of its industry peers.
ICLR's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 14.54%
PM (TTM) 9.25%
GM 29.08%
OM growth 3Y9.91%
OM growth 5Y-0.95%
PM growth 3Y50.65%
PM growth 5Y-6.44%
GM growth 3Y2.3%
GM growth 5Y-0.09%
ICLR Yearly Profit, Operating, Gross MarginsICLR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40

More info and screens

5

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), ICLR is destroying value.
The number of shares outstanding for ICLR has been reduced compared to 1 year ago.
The number of shares outstanding for ICLR has been increased compared to 5 years ago.
Compared to 1 year ago, ICLR has an improved debt to assets ratio.
ICLR Yearly Shares OutstandingICLR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
ICLR Yearly Total Debt VS Total AssetsICLR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

2.2 Solvency

An Altman-Z score of 2.23 indicates that ICLR is not a great score, but indicates only limited risk for bankruptcy at the moment.
ICLR has a Altman-Z score (2.23) which is in line with its industry peers.
The Debt to FCF ratio of ICLR is 3.23, which is a good value as it means it would take ICLR, 3.23 years of fcf income to pay off all of its debts.
ICLR has a better Debt to FCF ratio (3.23) than 75.93% of its industry peers.
ICLR has a Debt/Equity ratio of 0.36. This is a healthy value indicating a solid balance between debt and equity.
ICLR's Debt to Equity ratio of 0.36 is in line compared to the rest of the industry. ICLR outperforms 50.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.36
Debt/FCF 3.23
Altman-Z 2.23
ROIC/WACC0.89
WACC7.57%
ICLR Yearly LT Debt VS Equity VS FCFICLR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B

2.3 Liquidity

ICLR has a Current Ratio of 1.27. This is a normal value and indicates that ICLR is financially healthy and should not expect problems in meeting its short term obligations.
ICLR has a worse Current ratio (1.27) than 81.48% of its industry peers.
A Quick Ratio of 1.27 indicates that ICLR should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.27, ICLR is not doing good in the industry: 74.07% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.27
Quick Ratio 1.27
ICLR Yearly Current Assets VS Current LiabilitesICLR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

More info and screens

4

3. Growth

3.1 Past

The earnings per share for ICLR have decreased by -5.36% in the last year.
The Earnings Per Share has been growing by 15.23% on average over the past years. This is quite good.
The Revenue has been growing slightly by 1.99% in the past year.
ICLR shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 24.17% yearly.
EPS 1Y (TTM)-5.36%
EPS 3Y13.76%
EPS 5Y15.23%
EPS Q2Q%-13.07%
Revenue 1Y (TTM)1.99%
Revenue growth 3Y14.75%
Revenue growth 5Y24.17%
Sales Q2Q%-4.85%

3.2 Future

Based on estimates for the next years, ICLR will show a small growth in Earnings Per Share. The EPS will grow by 6.55% on average per year.
Based on estimates for the next years, ICLR will show a small growth in Revenue. The Revenue will grow by 2.07% on average per year.
EPS Next Y-3.4%
EPS Next 2Y1.8%
EPS Next 3Y4.24%
EPS Next 5Y6.55%
Revenue Next Year-3.96%
Revenue Next 2Y-1.17%
Revenue Next 3Y0.73%
Revenue Next 5Y2.07%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
ICLR Yearly Revenue VS EstimatesICLR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 2B 4B 6B 8B 10B
ICLR Yearly EPS VS EstimatesICLR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 5 10 15 20 25

More info and screens

6

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 14.14 indicates a correct valuation of ICLR.
98.15% of the companies in the same industry are more expensive than ICLR, based on the Price/Earnings ratio.
Compared to an average S&P500 Price/Earnings ratio of 28.04, ICLR is valued a bit cheaper.
Based on the Price/Forward Earnings ratio of 12.89, the valuation of ICLR can be described as correct.
Based on the Price/Forward Earnings ratio, ICLR is valued cheaper than 94.44% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of ICLR to the average of the S&P500 Index (37.64), we can say ICLR is valued rather cheaply.
Industry RankSector Rank
PE 14.14
Fwd PE 12.89
ICLR Price Earnings VS Forward Price EarningsICLR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

96.30% of the companies in the same industry are more expensive than ICLR, based on the Enterprise Value to EBITDA ratio.
ICLR's Price/Free Cash Flow ratio is rather cheap when compared to the industry. ICLR is cheaper than 94.44% of the companies in the same industry.
Industry RankSector Rank
P/FCF 14.05
EV/EBITDA 10.91
ICLR Per share dataICLR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 50 100

4.3 Compensation for Growth

ICLR has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.93
EPS Next 2Y1.8%
EPS Next 3Y4.24%

More info and screens

0

5. Dividend

5.1 Amount

ICLR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ICON PLC

NASDAQ:ICLR (7/25/2025, 8:00:01 PM)

After market: 187.01 0 (0%)

187.01

-8 (-4.1%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)07-23 2025-07-23/amc
Earnings (Next)10-21 2025-10-21/amc
Inst Owners101.17%
Inst Owner Change0.47%
Ins Owners0.63%
Ins Owner ChangeN/A
Market Cap14.86B
Analysts79.2
Price Target179.66 (-3.93%)
Short Float %2.64%
Short Ratio1.5
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.48%
Min EPS beat(2)-1.19%
Max EPS beat(2)0.23%
EPS beat(4)1
Avg EPS beat(4)-3.85%
Min EPS beat(4)-14.41%
Max EPS beat(4)0.23%
EPS beat(8)1
Avg EPS beat(8)-2.42%
EPS beat(12)4
Avg EPS beat(12)-1.63%
EPS beat(16)7
Avg EPS beat(16)-0.69%
Revenue beat(2)0
Avg Revenue beat(2)-2.08%
Min Revenue beat(2)-2.61%
Max Revenue beat(2)-1.54%
Revenue beat(4)0
Avg Revenue beat(4)-3.45%
Min Revenue beat(4)-6.75%
Max Revenue beat(4)-1.54%
Revenue beat(8)0
Avg Revenue beat(8)-2.81%
Revenue beat(12)0
Avg Revenue beat(12)-2.47%
Revenue beat(16)0
Avg Revenue beat(16)-2.13%
PT rev (1m)-1.6%
PT rev (3m)-15.83%
EPS NQ rev (1m)-0.43%
EPS NQ rev (3m)-4.06%
EPS NY rev (1m)-0.28%
EPS NY rev (3m)-3.16%
Revenue NQ rev (1m)0.35%
Revenue NQ rev (3m)-3.85%
Revenue NY rev (1m)-0.21%
Revenue NY rev (3m)-3.67%
Valuation
Industry RankSector Rank
PE 14.14
Fwd PE 12.89
P/S 1.81
P/FCF 14.05
P/OCF 12.1
P/B 1.56
P/tB N/A
EV/EBITDA 10.91
EPS(TTM)13.23
EY7.07%
EPS(NY)14.51
Fwd EY7.76%
FCF(TTM)13.31
FCFY7.12%
OCF(TTM)15.45
OCFY8.26%
SpS103.1
BVpS119.57
TBVpS-38.58
PEG (NY)N/A
PEG (5Y)0.93
Profitability
Industry RankSector Rank
ROA 4.53%
ROE 7.98%
ROCE 8.49%
ROIC 6.71%
ROICexc 6.97%
ROICexgc 100.08%
OM 14.54%
PM (TTM) 9.25%
GM 29.08%
FCFM 12.91%
ROA(3y)3.74%
ROA(5y)4.36%
ROE(3y)6.96%
ROE(5y)8.15%
ROIC(3y)5.8%
ROIC(5y)6.92%
ROICexc(3y)5.97%
ROICexc(5y)8.67%
ROICexgc(3y)88.82%
ROICexgc(5y)90.84%
ROCE(3y)7.34%
ROCE(5y)8.76%
ROICexcg growth 3Y-4.45%
ROICexcg growth 5Y-5.01%
ROICexc growth 3Y27.99%
ROICexc growth 5Y-24.17%
OM growth 3Y9.91%
OM growth 5Y-0.95%
PM growth 3Y50.65%
PM growth 5Y-6.44%
GM growth 3Y2.3%
GM growth 5Y-0.09%
F-Score7
Asset Turnover0.49
Health
Industry RankSector Rank
Debt/Equity 0.36
Debt/FCF 3.23
Debt/EBITDA 2.08
Cap/Depr 39.01%
Cap/Sales 2.07%
Interest Coverage 250
Cash Conversion 75.48%
Profit Quality 139.54%
Current Ratio 1.27
Quick Ratio 1.27
Altman-Z 2.23
F-Score7
WACC7.57%
ROIC/WACC0.89
Cap/Depr(3y)27.79%
Cap/Depr(5y)38.09%
Cap/Sales(3y)1.87%
Cap/Sales(5y)1.83%
Profit Quality(3y)130.43%
Profit Quality(5y)205.36%
High Growth Momentum
Growth
EPS 1Y (TTM)-5.36%
EPS 3Y13.76%
EPS 5Y15.23%
EPS Q2Q%-13.07%
EPS Next Y-3.4%
EPS Next 2Y1.8%
EPS Next 3Y4.24%
EPS Next 5Y6.55%
Revenue 1Y (TTM)1.99%
Revenue growth 3Y14.75%
Revenue growth 5Y24.17%
Sales Q2Q%-4.85%
Revenue Next Year-3.96%
Revenue Next 2Y-1.17%
Revenue Next 3Y0.73%
Revenue Next 5Y2.07%
EBIT growth 1Y8.27%
EBIT growth 3Y26.12%
EBIT growth 5Y22.99%
EBIT Next Year1.89%
EBIT Next 3Y4.21%
EBIT Next 5Y4.16%
FCF growth 1Y191.78%
FCF growth 3Y15.01%
FCF growth 5Y25.32%
OCF growth 1Y139.85%
OCF growth 3Y15.78%
OCF growth 5Y25.55%